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ABSTRACT
The tumor suppressor p53 has been studied exten-
sively as a direct transcriptional activator of protein-
coding genes. Recent studies, however, have shed
light on novel regulatory functions of p53 within non-
coding regions of the genome. Here, we use a sys-
tematic approach that integrates transcriptome-wide
expression analysis, genome-wide p53 binding pro-
files and chromatin state maps to characterize the
global regulatory roles of p53 in response to DNA
damage. Notably, our approach identified conserved
features of the p53 network in both human and mouse
primary fibroblast models. In addition to known p53
targets, we identify many previously unappreciated
mRNAs and long noncoding RNAs that are regulated
by p53. Moreover, we find that p53 binding occurs
predominantly within enhancers in both human and
mouse model systems. The ability to modulate en-
hancer activity offers an additional layer of complex-
ity to the p53 network and greatly expands the diver-
sity of genomic elements directly regulated by p53.
INTRODUCTION
The tumor suppressor p53 is an essential cellular stress sen-
sor and a central line of defense against genomic instability
(1–6). In response toDNAdamage p53 is stabilized and acts
as a transcription factor that directly regulates several hun-
dred genes and indirectly regulates thousandsmore (2). Tra-
ditionally, p53 has been thought to act through direct tran-
scriptional regulation of protein-coding genes. However, re-
cent reports have demonstrated functional roles for p53 that
extend beyond the coding genome.
One recently appreciated function of p53 within the non-
coding genome is the ability to regulate expression of long
noncoding RNAs (lncRNAs). Several lncRNAs have been
characterized as functionally important targets of p53 in
both mouse and human models (7,8). Among these RNAs
is lincRNA-p21, a lncRNA that has revealed a diversity
of functional roles ranging from regulation of apopto-
sis to translational suppression of complementary mR-
NAs (9,10). Another p53-regulated lncRNA, Pint, has been
shown to bind to Polycomb repressive complex 2 (PRC2)
and direct epigenetic silencing of genes involved with cel-
lular growth and proliferation in response to DNA damage
(11). Thewell-known oncogenic noncodingRNAPVT1 has
also been identified as a direct target of p53 in human cells,
although the exact functional role of PVT1 in the DNA
damage response remains unclear (12). The study of p53-
regulated lncRNAs is still in its infancy and these examples
likely represent a small subset of a larger class of lncRNAs
that has yet to be fully characterized.
Another recently uncovered role of p53 within the non-
coding genome is the recognition of regulatory enhancer
elements. An analysis of p53 binding events in human fi-
broblasts identified seven sites that occur within enhancer-
like regions (13). These p53-bound enhancers regulate the
expression of multiple genes over long distances via chro-
mosome looping. A detailed study of a single p53-bound
enhancer in Drosophila yielded similar results (14). These
common observations in distant organisms support the hy-
pothesis that enhancer regulation may be a general func-
tion of p53. However, the aforementioned studies were fo-
cused on isolated genomic loci and a comprehensive analy-
sis of enhancer recognition by p53 has not been performed
to date.
Here, we extend beyond previous genome-scale studies
on p53 regulation using a multifaceted and systematic ap-
proach that integrates transcriptome-wide differential ex-
*To whom correspondence should be addressed. Tel: +1 617 496 0586; Fax: +1 617 496 9679; Email: John Rinn@Harvard.edu
C© The Author(s) 2015. Published by Oxford University Press on behalf of Nucleic Acids Research.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which
permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
4448 Nucleic Acids Research, 2015, Vol. 43, No. 9
pression analysis, genome-wide p53 binding profiles, chro-
matin state maps and additional genomic features to inter-
rogate the global regulatory functions of p53 in response to
DNA damage. Furthermore, we have performed these anal-
yses in orthologous human and mouse fibroblast models to
better understand the conserved and divergent properties of
the p53 regulatory network across mammals. Collectively,
these data provide an unprecedented and comprehensive
overview of the p53 response to DNA damage in normal,
untransformed primary cells from both human and mouse.
In addition to p53-regulated genes identified in prior
studies, our approach has uncovered many previously un-
appreciated transcriptional targets of p53, including both
protein-coding genes and lncRNAs. The sequences of p53-
regulated lncRNAs are distinguished from the global tran-
scriptome in both human and mouse by their transposable
element (TE) composition, suggesting that specific TE se-
quences may influence the functional roles of these non-
coding RNAs in the DNA damage response. Interestingly,
the majority of p53 binding sites we detected fall within in-
tergenic regions not associated with direct transcriptional
regulation. The chromatin environment surrounding these
binding sites revealed that they are significantly enriched
within regulatory enhancer elements. Moreover, p53 bind-
ing sites occur much more frequently within annotated en-
hancers than within regions associated with transcription
start sites. Enhancers bound by p53 display a distinct tran-
scription factor co-occupancy landscape that indicates p53
likely functions as a dominant regulator of enhancer activ-
ity. Altogether, these multidimensional analyses emphasize
the importance of p53 beyond the direct transcriptional reg-
ulation of protein-coding genes and reveal that regulation
of enhancer elements is a predominant feature of the p53
response to DNA damage.
MATERIALS AND METHODS
Acquisition of publically available data sets
Repeat element sequences for both the human and mouse
genomes were obtained through the RepeatMasker tracks
from the UCSC Genome Browser. Histone ChIP-Seq data
sets used to generate chromatin state maps were obtained
from the Roadmap Epigenomics Project and the UCSC
Genome Browser. Human transcription factor binding sites
were obtained through the transcription factor ChIP-Seq
Clusters Version 3 track from the UCSC Genome Browser.
Mouse histone ChIP regions and transcription factor bind-
ing sites were obtained through the Ludwig Institute for
Cancer Research (LICR) tracks from the UCSC Genome
Browser.
Cell culture
Human fetal fibroblast lines GM00011 and GM06170
(Coriell Cell Repositories) were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
15% Fetal Bovine Serum (Life Technologies). MEFs were
generated from E13.5 embryos and cultured in DMEM
supplemented with 10% Fetal Bovine Serum. Human and
mouse fibroblasts were treated with 0.2 ug/ml doxorubicin
for 12 h and 6 h, respectively, to induce DNA damage.
RNA isolation and quantitative PCR
RNA from treated fibroblasts was isolated using TRIzol
(Life Technologies) as per the manufacturer’s instructions.
For each sample, 2 g of RNA was reverse transcribed
using SuperScript III Reverse Transcriptase (Life Tech-
nologies). RNA was treated with DNase I (Worthington)
prior to reverse transcription. qPCR was performed on
an ABI7900HT real-time PCR (Applied Biosystems) using
FastStart Universal SYBR Green Master––Rox (Roche).
Primers for TBP mRNA were supplied by Applied Biosys-
tems. All additional primers were designed using Primer3.
Only those primer sets that showed linear amplification over
several orders of magnitude were used for quantification.
Primers and PCR conditions are listed in Supplementary
Table S2.
Chromatin Immunoprecipitation
Human fibroblasts were crosslinked with 1% formaldehyde
in PBS (10 ml) for 10 min. The crosslinking reaction was
quenched with glycine (0.125M final concentration) for 5
min. Cells were collected and nuclei were isolated by two
successive washes with 5 ml cold hypotonic lysis buffer (10
mM Tris pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.5% Non-
idet P40). Pelleted nuclei were lysed in 1ml cold nuclear lysis
buffer (10 mM Tris pH 7.5, 1% Nonidet P40, 0.5% sodium
deoxycholate, 0.1% SDS, 1X Protease Inhibitor Cocktail)
and flash frozen in liquid nitrogen. DNA was sonicated on
ice to an average fragment size of ∼500 bp followed by
centrifugation to remove insoluble cell debris. Aliquots of
lysate (100 ul) were diluted to 1 ml in IP buffer (0.01% SDS,
1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris pH 8.0,
167 mMNaCl, 1× Protease Inhibitor Cocktail). Individual
aliquots were precleared for 1 hr with Proteain A/G Dyn-
abeads (Life Technologies). Antibodies were added to each
aliquot (4 ug/aliquot) and incubated at 4◦C overnight. Pro-
tein A/G Dynabeads (50 ul) were added to precipitate the
antibody complexes and the beads were successively washed
with 1 ml of the following wash buffers: low-salt (0.1%SDS,
1% Triton X-100, 2 mM EDTA, 20 mM Tris pH 8.0, 150
mM NaCl), high-salt (0.1%SDS, 1% Triton X-100, 2 mM
EDTA, 20 mM Tris pH 8.0, 500 mM NaCl), LiCL (0.25
M LiCl, 1% Nonidet P40, 1% sodium deoxycholate, 1 mM
EDTA, 10 mM Tris pH 8.0). Beads were then washed twice
with 1 ml TE pH 8.0. Complexes were eluted from beads
with two successive 250 ul incubations in elution buffer (1%
SDS, 0.1M NaHCO3). NaCl was added (final concentra-
tion 200 mM) and the samples heated to 65◦C overnight
to reverse crosslinks. The samples were then treated with
RNase A (1 ul) at 37◦C for 30 min, followed by the ad-
dition of Tris pH 7.0 (20 ul), 0.5 M EDTA (10 ul), and
proteinase K (20 ug) and incubation at 42◦C for 45 min.
DNA was isolated by phenol-chloroform extraction and
isopropanol precipitation. DNA pellets were resuspended
in 50 ul water. For ChIP-qPCR 2 ul of sample was used
per reaction and enrichment was calculated by comparison
with 1% of the corresponding input sample. -p53 (2524S),
-Phospho-p53-Ser15 (9284S) and normal IgG (2729S) an-
tibodies were supplied by Cell Signaling. -H3K4me1 (07–
436) and -H3K27ac (07–442) antibodies were supplied by
Millipore. Primers for lincRNA promoters and enhancers
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were designed using Primer3. Only those primer sets that
showed linear amplification over several orders of magni-
tude were used for quantification. Primers and PCR condi-
tions are listed in Supplementary Table S2.
RNA isolation and sequencing library construction
RNA from treated fibroblasts was isolated using TRIzol
(Life Technologies) as per the manufacturer’s instructions.
RNA was collected from two biological replicates for hu-
man fibroblasts and three biological replicates for mouse fi-
broblasts. RNA sequencing libraries were prepared with the
TruSeq RNA Sample Preparation Kit (Illumina) as per the
manufacturer’s instructions using 500 ng of input RNA for
each library. Prior to sequencing, the quality and concen-
tration of each library was assessed using the Bioanalyzer
(Agilent).
RNA sequencing and transcript alignment
RNA-Seq libraries were sequenced on a HiSeq 2000 (Il-
lumina). For characterization of protein-coding genes, se-
quencing reads were mapped to UCSC known genes for
human (hg19) or mouse (mm9) using TopHat2 with de-
fault options (15). For lincRNA characterization, sequenc-
ing reads were mapped to our previously described cata-
logs (generated from compendiums of human or mouse cell
lines) using TopHat2 with default options (16).
Gene expression analysis
Differential expression of protein-coding genes and lincR-
NAs in response to treatment with doxorubicin was as-
sessed using Cuffdiff2 with default options. The subset of
differentially expressed protein-coding genes classified as
significant byCuffdiff2 was further restricted to the top 75%
of expressed genes (based on FPKM values). The subset of
differentially expressed lincRNAs classified as significant by
Cuffdiff2 was further restricted to those with FPKM values
greater than 1 in at least one sample.
ChIP-Seq and ChIP-Seq analysis
ChIP experiments and ChIP-Seq library preparation were
performed as previously described (17). ChIP experiments
were carried out using a monoclonal antibody against p53
(DO-1, Santa Cruz) in human fibroblasts and a polyclonal
antibody against p53 (CM5, Vector Laboratories) inMEFs.
ChIP-Seq libraries were sequenced on a Genome Ana-
lyzer II (Illumina). ChIP-Seq reads were aligned to the hu-
man (hg19) or mouse (mm9) genomes using Bowtie2 (18).
Aligned reads were analyzed using Scripture (Broad) to
generate a catalog of potential ChIP peaks (19). To iden-
tify high confidence ChIP peaks, differential read coverage
between ChIP samples and their respective input samples
was assessed with Cuffdiff2 using the Scripture output as
a reference annotation. Peak intensities are represented us-
ing FPKM, which indicates ‘Fragments Per Kilobase Of
ChIP-Peak Per Million Fragments Mapped’. High confi-
dence ChIP peaks were further filtered to the top 75% of
read-covered peaks (based on FPKM values in the ChIP
samples). MEME-ChIP was used to analyze the presence
and distribution of sequencemotifs within ChIP peaks (20).
LincRNA: guilt by association and repeat sequence analysis
For guilt by association a pre-ranked list for each candi-
date RNAwas generated consisting of protein-coding genes
with similar expression profiles across a compendium of
cell/tissue types, with each gene ranked by its Jensen Shan-
non distance from the RNA of interest (16). The resulting
ranked list was subjected to Gene Set Enrichment Analy-
sis (Broad) using the Reactome gene sets from the Molec-
ular Signatures Database (21). For sequence motif identifi-
cation, the exon sequences of selected lincRNAs were ana-
lyzed with MEME using the default settings (22). Enrich-
ment of selected repeat elements was calculated by divid-
ing the normalized number of repeat element occurrences
within the selected subset of RNAs by the normalized num-
ber of occurrences within the transcriptome. For normal-
ization the number of occurrences within a data set (select
RNAs or transcriptome) was divided by the following ratio:
nucleotide coverage of the data set/nucleotide coverage of
the selected repeat element. To calculate statistical signifi-
cance of enrichment the labels of all RNAs within the tran-
scriptome were randomly shuffled and the analysis was re-
peated 100 times. The resulting p-values were corrected for
multiple hypothesis testing using the Bonferroni method.
Chromatin state map generation
To generate a general chromatin state map for human fi-
broblasts the state maps for several cell types were in-
tersected, resulting in a single map consisting of states
that were common to all cell types selected. The cell
types selected for this intersection were two unique hu-
man foreskin fibroblast samples, two unique human fore-
skin keratinocyte samples and normal human epidermal
keratinocytes (NHEKs). Chromatin state maps were gener-
ated from existing histone ChIP-Seq data for each individ-
ual cell type using ChromHMM (23). The specific histone
marks used to generate state maps for foreskin fibroblasts
and foreskin keratinocytes were H3K27ac, H3K27me3,
H3K36me3, H3K4me1, H3K4me3 and H3K9me3. The
state map for NHEKs also included H3K9ac. Histone
ChIP-Seq data sets for foreskin fibroblasts and foreskin ker-
atinocytes were acquired from the Roadmap Epigenomics
Project. Histone ChIP-Seq data for NHEKs were acquired
from the UCSC Genome Browser.
Chromatin state enrichment analyses
Enrichment of chromatin states was calculated by dividing
the normalized number of ChIP peaks overlapping a given
state by the number of peaks in the genome. For normal-
ization the number of ChIP peak overlaps within a data set
(chromatin state or whole genome) was divided by the fol-
lowing ratio: nucleotide coverage of the data set/nucleotide
coverage of ChIP peaks. To calculate statistical significance
of enrichment the labels of all chromatin states were ran-
domly shuffled and the analysis was repeated 100 times.
The resulting p-values were corrected for multiple hypothe-
sis testing using the Bonferroni method. The same analysis
was applied to mouse data with the exception that modified
histone ChIP-Seq peaks were used in place of chromatin
state maps.
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Transcription factor binding site enrichment analyses
For analysis of transcription factor binding sites within p53-
bound enhancers the annotated binding sites for each tran-
scription factor were intersected with the previously gen-
erated enhancer state map, resulting in a list of bound en-
hancers for each respective factor. Enrichment of transcrip-
tion factor binding site occurrence was calculated by di-
viding the normalized number of p53-bound enhancers in
common with a given transcription factor by the normal-
ized number of p53-bound enhancers within the genome.
For normalization the number of enhancers within a data
set (common enhancers or all enhancers) was divided
by the following ratio: nucleotide coverage of the data
set/nucleotide coverage of all p53-bound enhancers. To cal-
culate statistical significance of enrichment the labels of all
transcription factor-bound enhancers were randomly shuf-
fled and the analysis was repeated 100 times. The resulting
p-values were corrected for multiple hypothesis testing us-
ing the Bonferroni method. Significance analysis of global
transcription factor binding site co-occurrence within en-
hancers was calculated using the hypergeometric distribu-
tion given the number of enhancers overlapped by each fac-
tor under comparison and the total number of enhancers in
the genome. Resulting p-values were corrected for multiple
hypothesis testing using the Bonferroni method.
RESULTS
Identification of protein-coding genes that are directly regu-
lated by p53 in response to DNA damage in primary human
fibroblasts
As a model system to study transcriptional regulation by
p53 in response to DNA damage we treated cultured pri-
mary human fibroblasts with theDNAdouble-strand break
inducing agent doxorubicin. To recapitulate a normal p53-
dependent response to DNA damage we selected two un-
transformed human fetal fibroblast lines, GM00011 and
GM06170. The use of multiple cell lines also facilitates
the discrimination of general p53 properties from cell line-
specific observations. We isolated RNA from fibroblasts
cultured in the presence or absence of doxorubicin for 12
h and performed paired-end RNA-Sequencing (RNA-Seq)
with an average sequencing depth of 31.6 million mapped
fragments per sample.We then evaluated the differential ex-
pression of protein-coding genes in response to DNA dam-
age using the UCSC known genes annotation as a reference
transcriptome. Treatment with doxorubicin resulted in up-
regulation of 1365 mRNAs and down-regulation of 1598
mRNAs common to both cell lines (Figure 1A; Supplemen-
tary Table S1). Included in the list of up-regulated mRNAs
were well-established p53 target genes such as p21, PCNA
and PIG3 (Figure 1B).
While the DNA damage response results in differen-
tial expression of many genes, only a subset of these are
directly regulated by p53. To further distinguish direct
p53 target genes from those that are indirectly affected
by DNA damage we performed chromatin immunopre-
cipitation (ChIP) in doxorubicin-treated fibroblasts using
antibodies against p53. Isolated DNA was subjected to
single-end sequencing with an average depth of 21.9 million
uniquely mapped fragments per sample. ChIP-Sequencing
(ChIP-Seq) identified 4413 and 3174 p53 binding sites
in GM06170 and GM00011 cells, respectively. Compari-
son of p53 binding sites between fibroblast lines revealed
2638 sites common to both lines (Figure 1C). Motif anal-
ysis of the common p53 ChIP peaks using Multiple Em
for Motif Elicitation (MEME), specifically MEME-ChIP,
revealed enrichment of the p53 consensus binding mo-
tif, confirming the specificity of the ChIP experiment for
p53 binding sites (Figure 1D) (20). In addition, we per-
formed a highly stringent search for p53 binding motifs
(specifically [A/G]C[A/T][A/T]G[C/T][C/T][2–4 Spacer
Nucleotides][G/A][G/A]C[A/T][A/T]G[T/C]) within the
p53 ChIP peaks common to both fibroblast lines and iden-
tified clear motifs in 1074 of the 2638 peaks. The remaining
peaksmay have p53motifs that deviate slightly fromour cri-
teria. Alternatively, these peaks could arise indirectly from
distal regulatory elements that contain p53 motifs interact-
ing with their genomic targets (which may lack canonical
p53 motifs).
To further validate our ChIP-Seq results we compared
the p53 binding sites we identified to those described in
previous studies that performed p53 ChIP-Seq (24–26).
We observed appreciable, albeit incomplete, overlap in p53
binding sites between our data and the majority of data
sets we analyzed (Supplementary Figure S1A–C). Binding
sites characterized in cells treated with doxorubicin (lym-
phoblastoid or U2OS) displayed the most overlap with our
data (Supplementary Figure S1D). Altogether, 93% of the
p53 binding sites identified in our study were present in at
least one other data set. In contrast to the untransformed
fibroblasts from our study, these alternative studies used
cancer cell line models (MCF7, lymphoblastoid, or U2OS
cells). Moreover, they utilized a variety of methods for acti-
vating p53 as well as different antibodies in their ChIP pro-
tocols. These observations indicate that our ChIP-Seq re-
sults are not biased by the type of cells or antibodies used
in our experiments and are representative of a general re-
sponse to DNA damage by p53.
Unlike traditional transcription factors that bind within
a few hundred base pairs of transcription start sites (TSSs),
p53 has been shown in some cases to bind many kilobases
(kb) up- or downstream of its target genes. We empirically
evaluated the relationship between p53 ChIP peaks and
protein-coding gene TSSs, finding that most p53 binding
sites occur within 30 kb of an annotated TSS (Figure 1E).
Moreover, genes with p53 binding sites within 30 kb of their
TSSs had significantly higher levels of induction/repression
in response to DNA damage as compared to genes with-
out binding sites, further supporting that they are directly
regulated by p53 (Figure 1F). Based on these results we in-
tersected p53 ChIP peaks with genomic regions spanning
from 30 kb upstream to 30 kb downstreamof TSSs for genes
that were differentially expressed in response to DNA dam-
age, identifying a small subset of 262 up-regulated and 106
down-regulated genes that are direct targets of p53 (Fig-
ure 1G; Supplementary Table S1; Supplementary File 1). In
contrast to the noticeable level of variation in global gene
expression between GM06170 and GM00011 cells (Fig-
ure 1A), direct p53 target genes display consistent expres-
sion across cell lines (Figure 1G). The association of p53
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Figure 1. Identification of protein-coding genes that are directly regulated by p53 in response to DNA damage in primary human fibroblasts. (A) Heatmap
showing differential expression of protein-coding mRNAs in response to DNA damage. (B) RNA-Seq analysis of canonical p53 target genes in response
to DNA damage. (C) Overlap of p53 ChIP-Seq peaks from GM06170 and GM00011 fibroblasts. (D) Sequence motif analysis of p53 ChIP peaks. (E)
Distribution of p53 ChIP peaks relative to transcription start sites of protein-coding genes. (F) Cumulative distribution of expression changes for all p53
bound and unbound mRNAs in response to DNA damage. (G) Heatmap showing differential expression of direct p53 target mRNAs in response to DNA
damage. (H) RNA-Seq analysis of previously uncharacterized p53 target genes in response to DNA damage. (I) RNA-Seq and p53 ChIP-Seq at selected
loci. P-values (1F) were calculated using the Kolmogorov-Smirnov test.
with most of these genes has been previously unappreci-
ated, possibly because many have relatively low expression
compared to canonical p53 target genes (Figure 1H, Sup-
plementary File 1). RNA-Seq and p53 ChIP-Seq at the p21
locus (a well-known p53 target gene) and SLC4A11 locus
(an anti-apoptotic gene not previously associated with p53)
are shown in Figure 1I (27).
Identification of protein-coding genes that are directly regu-
lated by p53 in response to DNA damage in primary mouse
embryonic fibroblasts
The p53 protein, as well as its transcriptional regulation of
protein-coding gene targets, is highly conserved throughout
evolution (28). We reasoned that a systematic evaluation
of the DNA damage response in mouse fibroblasts might
shed light on the conserved functions of p53 within the non-
coding genome.We generated primary mouse embryonic fi-
broblasts (MEFs) and treated themwith doxorubicin for 6 h
to induceDNAdamage. RNAwas isolated fromMEFs and
subjected to paired-end RNA-Seq with an average sequenc-
ing depth of 29 million mapped fragments per sample. We
then evaluated the differential expression of protein-coding
genes in response to DNA damage using the UCSC known
genes annotation as a reference transcriptome.
Doxorubicin treatment resulted in up-regulation of 3124
mRNAs and down-regulation of 3334 mRNAs in MEFs
(Figure 2A; Supplementary Table S1). Included in the list
of up-regulated mRNAs were known p53 target genes such
as p21 and Mdm2 (Figure 2B). As in human cells, only a
subset of themouse genes that are differentially expressed in
response toDNAdamage represent direct targets of p53. To
further distinguish direct target genes we used a previously
published ChIP-Seq data set that we generated using anti-
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Figure 2. Identification of protein-coding genes that are directly regulated by p53 in response to DNA damage in primary mouse embryonic fibroblasts.
(A) Heatmap showing differential expression of protein-coding mRNAs in response to DNA damage. (B) RNA-Seq analysis of canonical p53 target genes
in response to DNA damage. (C) Sequence motif analysis of p53 ChIP peaks. (D) Distribution of p53 ChIP peaks relative to transcription start sites of
protein-coding genes. (E) Cumulative distribution of expression changes for all p53 bound and unbound mRNAs in response to DNA damage in wild-type
and p53−/− primary MEFs. (F) Heatmap showing differential expression of direct p53 target mRNAs in response to DNA damage. (G and H) RNA-Seq
analysis of previously uncharacterized p53 target genes in response to DNA damage in (G) wild-type and (H) p53−/− primary MEFs. (I) RNA-Seq and
p53 ChIP-Seq at selected loci. P-values (2E) were calculated using the Kolmogorov-Smirnov test.
bodies against p53 in doxorubicin-treated MEFs and iden-
tified 3100 binding sites (17). MEME-ChIP analysis of p53
ChIP peaks revealed enrichment of the p53 consensus bind-
ing motif, confirming the specificity of the ChIP experiment
for p53 binding sites (Figure 2C). A highly stringent search
for p53 binding motifs (using the previously described cri-
teria) within the p53 ChIP peaks in MEFs also identified
clear motifs in 900 of the 3100 peaks.
Most of the identified p53 binding sites occur within 20
kb of an annotated protein-coding gene TSS (Figure 2D).
Furthermore, genes with p53 binding sites within these re-
gions had significantly higher levels of induction/repression
in response to DNA damage as compared to genes without
binding sites (Figure 2E). Importantly, genes bound by p53
(in wild-type MEFs) were not induced/repressed in p53−/−
MEFs, demonstrating that they are directly regulated by
p53 (Figure 2E). Upon the intersection of p53 ChIP peaks
with genomic regions spanning from 20 kb upstream to 20
kb downstream of TSSs for genes that were differentially
expressed in response to DNA damage we identified a sub-
set of 585 up-regulated and 175 down-regulated genes that
are direct targets of p53 (Figure 2F; Supplementary Table
S1; Supplementary File 1). Our analysis uncovered many
genes that were previously uncharacterized as direct tar-
gets of p53, including orthologs of several genes detected
in our analysis of human fibroblasts (Figure 2G). Impor-
tantly, these genes were not induced in p53−/− MEFs in re-
sponse to DNA damage, confirming the ability of our ap-
proach to properly identify p53-regulated transcripts (Fig-
ure 2H). RNA-Seq and p53 ChIP-Seq at the p21 locus (a
well-known p53 target gene) and Slc4a11 locus (an ortholog
of the previously described human SLC4A11) are shown in
Figure 2I.
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p53 regulates expression of many lincRNAs in response to
DNA damage in primary human fibroblasts
Having characterized the protein-coding gene targets of p53
in response to DNA damage, we began evaluating p53’s
functional roles within the noncoding genome. We first ex-
amined the effects of DNA damage on noncoding RNA ex-
pression, specifically long intergenic noncoding RNAs (lin-
cRNAs). To characterize the differential expression of lin-
cRNAs in response to DNA damage we aligned the RNA-
Seq data generated from human fibroblasts to our previ-
ously reported comprehensive lincRNA reference catalog
(16). Doxorubicin treatment resulted in up-regulation of
101 lincRNAs and down-regulation of 32 lincRNAs com-
mon to both cell lines (Figure 3A; Supplementary Table S1).
We used p53 ChIP-Seq to distinguish direct target lincR-
NAs from those that are indirectly affected by DNA dam-
age. In contrast to protein-coding genes, most p53 bind-
ing sites occur within 45 kb of the nearest lincRNA TSS
(Figure 3B). However, to maintain consistency with our
previous analysis of protein-coding gene regulation in hu-
man fibroblasts we performed all subsequent analyses with
genomic regions spanning from 30 kb upstream to 30 kb
downstream of TSSs for annotated lincRNAs. LincRNAs
with p53 binding sites within these regions had significantly
higher levels of induction/repression in response to DNA
damage as compared to lincRNAs without binding sites,
supporting that they are directly regulated by p53 (Figure
3C). Similar to the ratio of p53 bound to unbound protein-
coding genes, we identified a subset of 22 up-regulated and
only 1 down-regulated lincRNA that are direct targets of
p53 (Figure 3D; Supplementary Table S1; Supplementary
File 1). A small fraction of the p53 binding sites associated
with lincRNA regulation (3/23) were also associated with
the regulation of transcripts characterized in our analysis
of protein-coding genes in human fibroblasts (Supplemen-
tary File 1).
Next, we randomly selected three of the p53-regulated
lincRNAs we identified for experimental validation. While
these lincRNAs had relatively low expression levels com-
pared to protein-coding genes, they were reproducibly in-
duced in both human fibroblast lines in response to DNA
damage (Figure 3E; Supplementary File 1). Moreover, our
RNA-Seq results closely resemble the transcript structures
of the lincRNA annotations within our reference cata-
log (Figure 3F). To experimentally confirm the existence
of these lincRNAs we extracted RNA from doxorubicin
treated GM00011 fibroblasts and performed RT-PCR (Fig-
ure 3G). We then performed quantitative RT-PCR (RT-
qPCR) and observed significant induction of all three lin-
cRNAs in response to doxorubicin treatment in GM00011
fibroblasts (Figure 3H). We also quantified p53 occupancy
at the promoters of all three lincRNAs using ChIP-qPCR
in GM00011 fibroblasts cultured in the presence or ab-
sence of doxorubicin. Interestingly, p53 was present at each
lincRNA promoter prior to doxorubicin treatment (Fig-
ure 3I). These results confirm that the lincRNAswe selected
for experimental validation are regulated by p53 and sug-
gest a model whereby p53 is actively poised at lincRNA
promoters to respond to DNA damage signals. Alterna-
tively, p53 could be actively repressing these lincRNAs in
untreated cells followed by a de-repression uponDNAdam-
age.
Biological properties and sequence features of human p53-
regulated lincRNAs
To understand the potential biological pathways associated
with p53-regulated lincRNAs we performed a ‘guilt by as-
sociation’ technique that correlates lincRNA and mRNA
expression profiles to infer common ontological features.
Briefly, we performed gene set enrichment analysis (GSEA)
using the gene ontology (GO) terms for protein-coding
genes that have expression patterns that are similar to each
lincRNA across a compendium of tissue/cell types (21,29).
Interestingly, all p53-regulated lincRNAs that were up-
regulated in response to DNA damage were strongly asso-
ciated with biological processes relevant to the DNA dam-
age response, including cell cycle checkpoints and DNA re-
pair (Figure 4A; Supplementary File 2). In contrast, the one
p53-regulated lincRNA that was down-regulated (denoted
by an * in Figure 4A) had negative associations with many
of these processes. While the ‘guilt-by-association’ analy-
sis is a correlation-based approach for inferring lincRNA
function as opposed to a direct demonstration of function,
our findings provide suggestive evidence that these lincR-
NAs may be involved in biological pathways relevant to the
DNA damage response.
To explore the sequence properties of p53-regulated lin-
cRNAs that may contribute to their biological functions
we performed motif analysis using MEME (22,30). We dis-
covered several sequence motifs that were significantly en-
riched within lincRNA transcripts that were up-regulated
in response to DNA damage (Figure 4B). However, none of
the enriched motifs resembled consensus binding sequences
for known RNA or DNA binding proteins. Intriguingly, all
of the identified motifs reside within Alu transposable el-
ements; no motifs were identified when repeat sequences
were masked. Subsequent enrichment analysis revealed that
p53-regulated lincRNAs are significantly enriched with sev-
eral families of transposable elements (TEs) relative to the
total transcriptome (Figure 4C). Collectively, TEs account
for nearly 47% of the total nucleotide coverage of p53-
regulated lincRNAs with Alu family elements being the
most commonly represented. Further analysis of individual
Alu family elements revealed AluSx as the most frequently
occurring element within p53-regulated lincRNAs, however
other Alu family members were also significantly enriched
(Figure 4D). Comparison of p53-regulated lincRNAs to the
reference lincRNA catalog, as opposed to the total tran-
scriptome, yielded nearly identical results (Supplementary
Figure S2A).
p53 regulates expression of many lincRNAs in response to
DNA damage in primary mouse embryonic fibroblasts
To investigate the similarities in lincRNA regulation be-
tween human and mouse we aligned the RNA-Seq data
generated from mouse fibroblasts to a lincRNA reference
catalog constructed using our previously described pipeline
with publically available RNA-Seq data sets (16). Doxoru-
bicin treatment resulted in up-regulation of 39 lincRNAs
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Figure 3. p53 regulates expression of many lincRNAs in response to DNA damage in primary human fibroblasts. (A) Heatmap showing differential
expression of lincRNAs in response to DNA damage. (B) Distribution of p53 ChIP peaks relative to transcription start sites of lincRNAs. (C) Cumulative
distribution of expression changes for all p53 bound and unbound lincRNAs in response to DNA damage. (D) Heatmap showing differential expression
of direct p53 target lincRNAs in response to DNA damage. (E) RNA-Seq analysis of p53 target lincRNAs in response to DNA damage. (F) RNA-Seq
and p53 ChIP-Seq at selected lincRNA loci. (G) RT-PCR detection of p53 target lincRNAs in GM00011 cells. (H) RT-qPCR showing induction of p53
target lincRNAs in response to DNA damage. (I) ChIP-qPCR analysis of p53 occupancy at lincRNA promoters in response to DNA damage. P-values
(3C) were calculated using the Kolmogorov-Smirnov test. Error bars (3H and 3I) indicate SEM (n = 3). P-values (3H and 3I) were calculated using the
two-tailed unpaired Student’s t-test with equal variances. *P < 0.05, **P < 0.01.
and down-regulation of 20 lincRNAs (Figure 5A; Supple-
mentary Table S1). We then used p53 ChIP-Seq to differen-
tiate direct target lincRNAs from those that are indirectly
affected by DNA damage. Similar to our observations in
human cells, p53 binding sites in MEFs had a wider distri-
bution with respect to the TSS of their nearest respective
lincRNA (Figure 5B). However, to remain consistent with
our previously analysis of protein-coding gene regulation
in MEFs we intersected p53 ChIP peaks with genomic re-
gions spanning from 20 kb upstream to 20 kb downstream
of TSSs for annotated lincRNAs. LincRNAswith p53 bind-
ing sites within these regions had significantly higher lev-
els of induction/repression in response to DNA damage as
compared to lincRNAs without binding sites (Figure 5C).
In addition, lincRNAs bound by p53 (in wild-type MEFs)
were not induced/repressed in p53−/− MEFs, indicating
that they are direct p53 targets (Figure 5C and D). Im-
portantly, the p53-regulated lincRNAs we identified in our
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Figure 4. Biological properties and sequence features of human p53-
regulated lincRNAs. (A) Guilt by association analysis of p53-regulated
lincRNAs. (B) Sequence motif analysis of lincRNAs regulated by p53.
(C) Enrichment analysis of transposable element families within lincRNAs
regulated by p53. (D) Enrichment analysis of Alu family elements within
lincRNAs regulated by p53.
RNA-Seq results closely resemble the transcript structures
of the lincRNA annotations within our reference catalog
(Figure 5E). Relative to human cells, a similar fraction of
differentially expressed lincRNAs (21 up-regulated and 4
down-regulated) was directly regulated by p53 in MEFs
(Figure 5F; Supplementary Table S1; Supplementary File
1). A subset of the p53 binding sites associated with lin-
cRNA regulation (8/25) were also associated with the regu-
lation of transcripts characterized in our analysis of protein-
coding genes in MEFs (Supplementary File 1).
We next searched for sequence motifs that are enriched
within the subset of p53-regulated lincRNA transcripts that
were up-regulated in response to DNA damage in MEFs.
Using MEME we identified several significantly enriched
motifs (Figure 5G). There were no obvious similarities be-
tween motifs found in human and mouse at the nucleotide
level, but many of the motifs identified in mouse lincR-
NAs occur within B1 TEs which share ancestral history
with human Alu elements (31). Enrichment analysis re-
vealed that B1 elements are the most prevalent TE family
found within p53-regulated lincRNAs and are significantly
enriched relative to the total transcriptome (Figure 5H).
Themost frequently occurringmember of the B1 family was
Mus1, although several additional B1 family members were
also significantly enriched (Figure 5I). Comparison of p53-
regulated lincRNAs to the reference lincRNA catalog, as
opposed to the total transcriptome, yielded highly similar
results (Supplementary Figure S2B).
p53 binding occurs predominantly within enhancer regions in
primary human fibroblasts
Following our analysis of p53-regulatedmRNAs and lincR-
NAs we found that the majority of p53 binding sites were
not associated with direct transcriptional regulation. Only
12.9% (340/2638) of p53 binding sites in human fibroblasts
were associated with regulation of nearby transcripts de-
spite our use of large regulatory windows spanning from
30 kb upstream to 30 kb downstream of TSSs. These ob-
servations suggest that p53 may have alternative functions
within the noncoding genome. The recent development of
chromatin state maps has been instrumental in deciphering
the regulatory characteristics of genomic regions (32,33).
Briefly, chromatin state maps utilize combinatorial patterns
of histone modifications to infer the regulatory capacity of
genomic elements. We reasoned that these maps could be
used to determine the functional importance of p53 bind-
ing sites.
To generate a chromatin state map for our analysis we in-
tersected state maps from two independent foreskin fibrob-
last samples. In addition, we utilized maps from cell types
that are functionally distinct from fibroblasts to identify
states that are common to a variety of cell types and further
increase the stringency of our approach. Because the human
fibroblast cell lines in our studywere both isolated from fetal
skin tissue, we chose maps from keratinocyte lines includ-
ing normal human epidermal keratinocytes (NHEKs) and
two independent foreskin keratinocyte samples. The hybrid
chromatin state map used in our study was restricted to ge-
nomic regions that have the same predicted chromatin state
across all of the aforementioned samples.
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Figure 5. p53 regulates expression of many lincRNAs in response to DNA damage in primary mouse embryonic fibroblasts. (A) Heatmap showing dif-
ferential expression of lincRNAs in response to DNA damage. (B) Distribution of p53 ChIP peaks relative to transcription start sites of lincRNAs. (C)
Cumulative distribution of expression changes for all p53 bound and unbound lincRNAs in response to DNA damage in wild-type and p53−/− primary
MEFs. (D) RNA-Seq analysis of a p53 target lincRNA in response to DNA damage in wild-type and p53−/− primaryMEFs. (E) RNA-Seq and p53 ChIP-
Seq at selected lincRNA locus. (F) Heatmap showing differential expression of direct p53 target lincRNAs in response to DNA damage. (G) Sequence
motif analysis of lincRNAs regulated by p53. (H) Enrichment analysis of transposable element families within lincRNAs regulated by p53. (I) Enrichment
analysis of B1 family elements within lincRNAs regulated by p53. P-values (5C) were calculated using the Kolmogorov-Smirnov test.
We intersected our experimentally determined p53 bind-
ing sites identified using ChIP-Seq with the hybrid chro-
matin state map and made two notable observations. First,
we found that enhancers are among themost common regu-
latory element in which p53 binding sites occur (Figure 6A;
Supplementary File 3). Binding sites are much less frequent
in regions of weak transcription, a state that covers 10 times
more genomic space than enhancers in our map annota-
tions (Figure 6A). These findings demonstrate that our ob-
servations are not a function of the genomic space covered
by individual states. Second, p53 binding sites are signifi-
cantly enriched within enhancer elements when compared
to genomic background (Figure 6A). Collectively, these ob-
servations indicate that recognition of enhancer elements is
a predominant feature of p53 in response to DNA damage.
To validate the role of p53 in enhancer regulation
we selected three genomic regions to interrogate using
ChIP-qPCR. We termed these regions ‘Enhancer Region-
1’ (chr17:67,603,115–67,604,105), ‘Enhancer Region-2’
(chr6:37,212,381–37,213,509) and ‘Unannotated Region-1’
(chr9:84,635,978–84,636,899). Of these regions, ‘Enhancer
Region-1’ and ‘Enhancer Region-2’ were annotated as en-
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Figure 6. p53 regulation occurs predominantly within enhancer regions in primary human fibroblasts. (A) Enrichment analysis of p53 binding sites within
annotated chromatin states. (B-E) ChIP-qPCR analysis of (B) p53, (C) phospho-p53, (D) H3K4me1 and (E) H3K27ac at enhancers in response to DNA
damage. (F) Enrichment analysis of transcription factor binding sites within p53-bound enhancers. (G) Global analysis of transcription factor binding
site co-occurrence significance within annotated enhancers. Error bars (6B, 6C, 6D and 6E) indicate SEM (n = 3). P-values (6B, 6C, 6D and 6E) were
calculated using the two-tailed unpaired Student’s t-test with equal variances. **P < 0.01.
hancers in our chromatin state map. In contrast, ‘Unanno-
tated Region-1’ was not represented in our state map and
was selected to explore the potential functions of p53 bind-
ing sites outside of our annotated chromatin states. We first
quantified p53 occupancy within these regions in GM00011
fibroblasts cultured in the presence or absence doxorubicin.
We were able to detect p53 binding at all three regions in
both untreated and doxorubicin treated fibroblasts (Fig-
ure 6B). These results suggest that, similar to lincRNA pro-
moters, p53 is actively poised at these sites to respond to
DNA damage signals. To test this hypothesis we performed
ChIP-qPCR with antibodies against an activated form of
p53 that has been phosphorylated at the N-terminal serine-
15 (34,35). In response to doxorubicin treatment we ob-
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served significant enrichment of activated p53 at all three
sites (Figure 6C). These findings confirm that p53 is poised
for activation at the examined regions and further indicate
that the p53 binding sites identified in this study are actively
responding to DNA damage signals.
To verify that the regions we selected for investigation are
actually enhancers we next evaluated their local chromatin
environment. More specifically, we performed ChIP-qPCR
with antibodies that recognize mono-methylated histone-3-
lysine-4 (H3K4me1), a hallmark chromatin signature of en-
hancer activity (36). We detected the presence of H3K4me1
at all three regions in both untreated and doxorubicin
treated fibroblasts (Figure 6D). These results confirm that
both ‘Enhancer Region-1’ and ‘Enhancer Region-2’ are
correctly annotated as enhancers in our chromatin state
map. Furthermore, they identify ‘Unannotated Region-1’
as an enhancer and indicate that many of the p53 bind-
ing sites that do not overlap regions annotated in our state
map may also function at enhancers. To determine if ‘En-
hancer Region-1’, ‘Enhancer Region-2’ and ‘Unannotated
Region-1’ are functional enhancers in GM00011 fibroblasts
we quantified the levels of histone-3-lysine-27 acetylation,
a chromatin signature of active enhancers, present at these
regions (37). We found that all three regions were marked
by H3K27 acetylation in both untreated and doxorubicin
treated fibroblasts (Figure 6E). Interestingly, we observed
a significant decrease in H3K27 acetylation in response to
doxorubicin treatment (Figure 6E). Collectively, these re-
sults indicate that p53 binds to functional enhancers and
may modulate their regulatory activity.
Enhancers are regulatory elements that influence gene
transcription from distant genomic locations (38–41). One
hallmark of enhancers is the presence of multiple tran-
scription factor (TF) binding sites that provide a platform
for combinatorial gene regulation by multiple factors (42–
44). To determine if p53 functions in concert with addi-
tional TFs we evaluated TF occupancy within p53-bound
enhancers. Using publically available ChIP-Seq data sets
collected from a variety of cell types we found that bind-
ing sites for several TFs are enriched within p53-bound en-
hancers relative to all annotated enhancers (Figure 6F). In-
cluded within the list of significantly enriched factors is the
transcriptional repressor KAP1 which has been previously
shown to interact with p53 (45–47). RNA Polymerase II
and p300 are among the most frequently occurring factors
within p53-bound enhancers, but their occupancy is a gen-
eral property of enhancer elements explaining their lack of
enrichment. Other factors, such as JunD which has been
shown to function in opposition to p53, are significantly de-
pleted from p53-bound enhancers (48).
To determine how the enrichment of TFs within p53-
bound enhancers compares with global TF co-occupancy
we assessed the significance of transcription factor binding
site co-occurrence between all factors within all annotated
enhancer elements. Intriguingly, p53 is among the few TFs
that display no significant co-occurrence with any other fac-
tors (Figure 6G). In contrast, binding site co-occurrence of
the well-characterized interacting factors cFos and cJun is
highly significant. These results suggest that, while specific
TFs are significantly enriched within p53-bound enhancers,
the co-occurrence of binding sites for these factors is not
a distinguishing characteristic of enhancers bound by p53.
This observation implies that recognition of enhancers by
p53 is not strongly influenced by or dependent on additional
TFs and that p53 may have the capacity to act alone as a
dominant regulator of enhancer activity.
p53 binding occurs predominantly within enhancer regions in
primary mouse embryonic fibroblasts
The significant enrichment of p53 binding sites within en-
hancer elements in human fibroblasts prompted us to in-
vestigate the relationship between p53 and enhancers in
the DNA damage response in mouse fibroblasts. Chro-
matin state maps have not yet been generated for the
mouse genome, however several ChIP-Seq data sets are
available that can serve as viable alternatives for infer-
ring chromatin states. We selected ChIP-Seq data gener-
ated by the Ludwig Institute for Cancer Research (LICR)
as they provided the most comprehensive list of histone and
TF ChIP-Seq profiles relevant to our study (49). Included
in this list were histone-3-lysine-27-acetlyation (H3K27ac;
indicating general regulatory elements), histone-3-lysine-
4-monomethylation (H3K4me1; indicating enhancer ele-
ments), histone-3-lysine-4-trimethylation (H3K4me3; in-
dicating active promoters), histone-3-lysine-9-acetylation
(H3K9ac; indicating active promoters), histone-3-lysine-
27-trimethylation (H3K27me3; indicating repressed chro-
matin) and histone-3-lysine-36-trimethylation (H3K36me3;
indicating gene bodies) for heart tissue and embryonic stem
cells. In addition, ChIP-Seq profiles for RNAPolymerase II
and p300 were available for these cell types. We included hi-
stone ChIP-Seq profiles generated from MEFs in our anal-
yses, but corresponding data for p300 were not available in
these cells.
We intersected our experimentally determined p53 bind-
ing sites from MEFs with the LICR histone ChIP-Seq
profiles and found that, similar to human cells, p53 bind-
ing occurs most frequently within enhancer (H3K4me1)
regions (Figure 7A). Furthermore, enrichment of binding
sites within enhancers is comparable to active promoters
(H3K4me3 and H3K9ac). Binding sites are most highly
enriched within general regulatory regions (H3K27ac),
which are inclusive of both active promoters and en-
hancers. Conversely, enrichment of binding sites within re-
gions of repressed chromatin (H3K27me3) and gene bodies
(H3K36me3) was not significant. Collectively, these find-
ings suggest that the prevalence of enhancer recognition by
p53 is conserved across mammals.
We next intersected p53 binding sites with the LICR
TF ChIP-Seq profiles and observed that binding occurs
most frequently in regions associated with p300, a hallmark
enhancer-binding protein (Figure 7B). Moreover, the en-
richment of binding sites within p300-associated regions is
equivalent to RNA Polymerase II-associated regions when
compared to genomic background. We observed no sig-
nificant enrichment of p53 binding sites within CTCF-
associated regions, which typically demarcate insulator ele-
ments. These findings demonstrate the selectivity of p53 for
enhancers as compared to other regulatory elements.
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Figure 7. p53 regulation occurs predominantly within enhancer-like re-
gions in primary mouse embryonic fibroblasts. (A) Enrichment analysis
of p53 binding sites within modified chromatin across several mouse cell
types. (B) Enrichment analysis of transcription factor co-occurrence with
p53 binding sites across several mouse cell types.
DISCUSSION
Direct transcriptional regulation of protein-coding genes by
p53 in response to DNA damage has been studied for more
than 20 years. The application of genome-scale approaches
has been particularly useful in elucidating novel aspects of
global gene regulation within the p53 network. However,
improved genomic technologies/methodologies as well as
advances in our understanding of genome regulation pro-
vide an opportunity to perform an updated assessment of
p53 functions throughout the genome. Here, we have uti-
lized a systematic approach that integrates transcriptome-
wide differential expression analysis with genome-wide p53
binding profiles in orthologous human and mouse fibrob-
last models and have identified many previously unappreci-
ated transcriptional targets of p53. Moreover, we have in-
corporated the use of chromatin state maps along with ad-
ditional transcription factor binding profiles and character-
ized the regulatory properties of p53 binding sites within
noncoding regions of the genome.
Alongside canonical p53 targets, our analysis identified a
large number of protein-coding genes that were not previ-
ously characterized as direct targets of p53 (24,26,50–53).
Importantly, our study was performed in primary fibrob-
lasts and the p53 target genes we have identified may rep-
resent constituents of the DNA damage response that be-
come improperly regulated in cancer. The majority of these
genes displayed relatively low expression, which might also
explain why they have eluded detection in previous studies
that utilized less sensitive methods. Despite their low ex-
pression, regulation by p53 for many of these underappre-
ciated targets is conserved between human and mouse sug-
gesting that they may be important components of the p53
response to DNA damage. Future experimental validation
will be necessary to characterize the functional roles of these
genes in the DNA damage response.
In addition to protein-coding genes, our analysis identi-
fied several lincRNAs that are direct transcriptional targets
of p53 in both mouse and human. In contrast to protein-
coding genes, we did not find detectable orthology between
p53-regulated lincRNAs in human and mouse with respect
to either sequence composition or shared synteny. How-
ever, there were commonalities in the sequence properties of
p53-regulated lincRNAs between species. Specifically, p53-
regulated lincRNAs are significantly enriched with Alu TEs
in human and the related B1 TEs in mouse. Enrichment
of Alu TEs is a distinguishing feature of p53-regulated lin-
cRNAs as previous studies have described a depletion of
these elements within lincRNAs in general (54). Alu TEs
have been implicated in gene regulation through various
mechanisms. For example, Alu elements are enrichedwithin
the promoter regions of genes involved in cell prolifera-
tion and contain binding sites for multiple TFs that reg-
ulate gene expression (55,56). LincRNAs containing Alu
sequences could plausibly sequester Alu-binding TFs and
inhibit cell proliferation in response to DNA damage (57).
Alternatively, noncoding RNAs containing Alu sequences
can hybridize to complementary Alu sequences within 3′-
untranslated regions (3′ UTRs) of protein-coding tran-
scripts and recruit proteins that induce mRNA decay (58).
Alu elements are enriched in 3′ UTRs of transcripts that en-
code proteins involved in metabolism and signal transduc-
tion, making these mRNAs relevant targets for degradation
in response to DNA damage (59). Detailed investigation of
individual lincRNAs will be required to test these possibil-
ities.
Perhaps the most pronounced observation in our study
was the prevalence of p53 binding sites within regulatory
enhancer elements. Although recent experimental reports
have demonstrated that p53 has the capacity to regulate
gene expression through recognition of enhancer elements,
the widespread nature of p53 binding to enhancers has not
been previously characterized (13,14,60,61). Here, we pro-
vide strong evidence that enhancer recognition is actually
a predominant feature of the p53 response to DNA dam-
age. The generally accepted capacity of p53 to influence
gene expression over large genomic distances is a hallmark
attribute of enhancers and strongly supports our observa-
tions.
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Recognition of enhancer elements by p53 could result in
diverse functional outcomes. Two recent reports have char-
acterized individual p53-bound enhancers that interact with
distal genes via chromosomal looping and induce gene ex-
pression (13,14). In contrast, a study in mouse embryonic
stem cells revealed that p53 inhibits the expression of core
transcription factors by binding and interfering with the ac-
tivity of distal enhancers (60). The ability of p53 to inhibit
enhancer activity is especially intriguing given our obser-
vation that p53-bound enhancers are significantly enriched
with KAP1 interacting sites. KAP1 is a transcriptional re-
pressor that interacts with chromatin modifiers and orches-
trates heterochromatin formation (62,63). KAP1 binding is
typically associated with H3K9-trimethylation, a repressive
mark that has been shown to regulate enhancer activity (64).
Interestingly, KAP1 lacks a clearDNAbinding domain and
requires additional factors for recruitment to its targets. In-
teractions between p53 and KAP1 have been reported, sup-
porting the hypothesis that KAP1may be an important fac-
tor in enhancer repression by p53 (45–47). Although KAP1
is expressed in the fibroblast lines used in this study, we
were unable to identify ChIP-grade antibodies despite re-
peated attempts. Nevertheless, our observation of decreased
H3K27 acetylation at p53-bound enhancers in doxorubicin
treated fibroblasts is consistent with a potential role for p53
in enhancer repression.
In conclusion, our findings have provided new insight
into p53 biology and expanded our understanding of
genome regulation by p53. In addition to its roles in the
DNA damage response, p53 is an integral component of
normal cellular differentiation and development (65). En-
hancer regulation by p53 is likely a key factor in these pro-
cesses as well, a hypothesis that is supported by our finding
that p53 binding is significantly enriched within enhancer
regions in mouse embryonic stem cells (Figure 7A and B).
Furthermore, the biological necessity of p53 has been ex-
perimentally validated in organisms as primitive as the sea
anemone and it will be interesting to evaluate the prevalence
of enhancer regulation by p53 throughout evolution (66).
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